Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) [2] (multiple letters)

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 5, 2004, Pages 505-506

  Tobin, Peter ^a   Rivory, Laurent ^b   Clarke, Stephen ^c   Blandizzi, Corrado ^d   Danesi, Romano ^d   De Paolis, Barbara ^d   Di Paolo, Antonello ^d   Colucci, Rocchina ^d   Del Tacca, Mario ^d   Falcone, Alfredo ^e  

^a Australia   (Australia)

^b Italy ^*  (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

^d UNIVERSITY OF PISA   (Italy)

^e Livorno Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE DERIVATIVE; ACETYLCHOLINESTERASE; BIOLOGICAL MARKER; CAMPTOTHECIN 11; IRINOTECAN;

ABDOMINAL PAIN; BLOOD SAMPLING; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAPHORESIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ERYTHROCYTE LEVEL; HEMOCONCENTRATION; HUMAN; IC 50; LETTER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VOMITING;

EID: 7944228947     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.07.014     Document Type: Letter

References (0)